Genentech Sues Apotex Over Generic Valcyte
Genentech and Roche Palo Alto LLC's complaint claims Apotex infringed U.S. Patent Number 6,083,953 by seeking U.S. Food and Drug Administration approval for a generic version of Valcyte, and seeks to block the Canadian drugmaker from selling its product in the U.S. before that patent expires.
“Apotex threatens to market and sell the Apotex generic product in California and elsewhere in the...
Already a subscriber? Click here to login